Back to Search
Start Over
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)
- Source :
- Journal of Clinical Oncology. 34:4568-4568
- Publication Year :
- 2016
- Publisher :
- American Society of Clinical Oncology (ASCO), 2016.
-
Abstract
- 4568Background: CB-839 is a selective inhibitor of GLS, a key enzyme in the utilization of glutamine by many cancer cells. CB-839 has broad activity in preclinical models, including RCC where GLS i...
- Subjects :
- 0301 basic medicine
chemistry.chemical_classification
Cancer Research
Everolimus
business.industry
Glutaminase
Pharmacology
Small molecule
Glutamine
03 medical and health sciences
030104 developmental biology
Enzyme
Oncology
chemistry
Cancer cell
Medicine
Cell cancer
In patient
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........f5fb8db254833e258141082bd3afe928
- Full Text :
- https://doi.org/10.1200/jco.2016.34.15_suppl.4568